BC
BLUE

Barrett & Company’s bluebird bio BLUE Stock Holding History

Barrett & Company’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed -$256 – 600
2024
Q1 		$256 Hold
10
– – ﹤0.01% 602
2023
Q4 		$276 Hold
10
– – ﹤0.01% 597
2023
Q3 		$608 Hold
10
– – ﹤0.01% 597
2023
Q2 		$658 Hold
10
– – ﹤0.01% 577
2023
Q1 		$636 Hold
10
– – ﹤0.01% 562
2022
Q4 		$1.38K Hold
10
– – ﹤0.01% 536
2022
Q3 		$1.38K Buy
+10
New +$1.13K ﹤0.01% 536

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barrett & Company's BLUE Position: Q2 2024 in Review

Barrett & Company sold out of bluebird bio (BLUE) in Q2 2024, closing a stake of 10 shares — an estimated $256 sold.

Barrett & Company first reported a position in BLUE in Q3 2022 and held it in 7 quarters. The position peaked at $1.38K in Q4 2022. 150 funds tracked by Wall St. Rank hold BLUE as of Q2 2024.

  • Barrett & Company reported no remaining bluebird bio position as of Q2 2024 after selling out during the quarter.
  • Barrett & Company sold 10 bluebird bio shares in Q2 2024, an estimated $256.
  • Barrett & Company first reported a position in bluebird bio in Q3 2022 and held it in 7 quarters.
  • Barrett & Company's bluebird bio position peaked at $1.38K in Q4 2022.
  • 150 funds tracked by Wall St. Rank held bluebird bio as of Q2 2024.

Based on Barrett & Company's 13F filing for Q2 2024, filed 25 Jul 2024.